ChiCTR2100051876 版本V1.2 版本创建时间2021/10/08 02:22:00 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100051876 

最近更新日期:

Date of Last Refreshed on:

2021-10-08 02:19:34 

注册时间:

Date of Registration:

2021-10-08 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

综合支持方案对头颈部肿瘤放射治疗患者口干症、唾液特征和口腔健康的影响: 一项随机对照试验

Public title:

The effects of an integrated supportive programme on xerostomia, salivary characteristics and oral health in patients with head and neck cancer undergoing radiotherapy: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

综合支持方案对头颈部肿瘤放射治疗患者口干症、唾液特征和口腔健康的影响: 一项随机对照试验

Scientific title:

The effects of an integrated supportive programme on xerostomia, salivary characteristics and oral health in patients with head and neck cancer undergoing radiotherapy: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

姜男 

研究负责人:

姜男 

Applicant:

Nan Jiang 

Study leader:

Nan Jiang 

申请注册联系人电话:

Applicant telephone:

+86 15822773672

研究负责人电话:

Study leader's
telephone:

+86 15822773672

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

nan.jiang@ju.se

研究负责人电子邮件:

Study leader's E-mail:

nan.jiang@ju.se

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

天津市和平区气象台路22号

研究负责人通讯地址:

天津市和平区气象台路22号

Applicant address:

22 Observatory Road, Heping District, Tianjin, China

Study leader's address:

22 Observatory Road, Heping District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

300070

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津医科大学

Applicant's institution:

Tianjin Medical University

研究负责人所在单位:

天津医科大学

Affiliation of the Leader:

Tianjin Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

TMUHMEC 2015008

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津医科大学伦理委员会

Name of the ethic committee:

Tianjin Medical University Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

戚红

Contact Name of the ethic committee:

Hong Qi

伦理委员会联系地址:

天津市和平区气象台路22号

Contact Address of the ethic committee:

Tianjin Medical University, 22 Observatory Rd, Heping District, Tianjin 300070, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津医科大学

Primary sponsor:

Tianjin Medical University

研究实施负责(组长)单位地址:

天津市和平区气象台路22号

Primary sponsor's address:

Tianjin Medical University, 22 Observatory Rd, Heping District, Tianjin 300070, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学

具体地址:

和平区气象台路22号

Institution
hospital:

Tianjin Medical University

Address:

22 Observatory Road, Heping District

经费或物资来源:

天津市教委科研计划项目

Source(s) of funding:

Scientific Research Program of Tianjin Education Commission

研究疾病:

头颈部肿瘤  

Target disease:

Head and neck cancer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价综合支持方案对头颈部肿瘤放射治疗患者的口干、唾液特征和口腔健康的影响  

Objectives of Study:

to determine the effects of an integrated supportive programme on xerostomia, salivary characteristics and oral health in patients with head and neck cancer undergoing radiotherapy

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

经组织病理学确诊为头颈部肿瘤,年龄18岁或以上,KPS评分为80-100,治疗方案为单纯放射治疗(剂量≥60Gy)或术后放疗联合同步放化疗或诱导化疗,以及能够完成放疗后12个月的随访和复查。

Inclusion criteria

Patients with: a histological diagnosis of HNC; an age of 18 years or older; a Karnofsky Performance Scale Index (KPS) of 80-100; primarily received definitive RT for curative or surgery with postoperative RT for curative (dose of ≥ 60 grey) with concurrent or induction chemotherapy or both; and the ability to attend regular re-examination during the 12-month follow-up.

排除标准:

患有其他癌症、有其他原因引起的口干症(如干燥综合征、糖尿病、使用干扰唾液流动的药物、切除双侧唾液腺)、严重认知障碍(如痴呆)或患有无法完成问卷填写的精神疾病。

Exclusion criteria:

Patients with total edentulism; other cancer; other causes of xerostomia (i.e., Sj?gren syndrome, diabetes mellitus, use of drugs that could interfere with salivary flow, removed bilateral salivary glands); or severe cognitive impairment (i.e., dementia) or psychiatric disorders that interfered with the ability to complete the questionnaire package.

研究实施时间:

Study execute time:

From 2019-02-24 00:00:00 To 2020-09-25 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-02-17 00:00:00 To 2019-08-08 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

40

Group:

Intervention group

Sample size:

干预措施:

综合支持方案和常规护理

干预措施代码:

Intervention:

Integrated supportive programme and usual care

Intervention code:

组别:

对照组

样本量:

39

Group:

Control group

Sample size:

干预措施:

常规护理

干预措施代码:

Intervention:

Usual care

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Tianjin Cancer Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

口干问卷

指标类型:

主要指标

Outcome:

Xerostomia Questionnaire

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

唾液pH值

指标类型:

主要指标

Outcome:

pH

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

非刺激唾液分泌率

指标类型:

主要指标

Outcome:

Unstimulated salliva flow rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

唾液缓冲能力

指标类型:

主要指标

Outcome:

buffering capacity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

龋失补指数

指标类型:

主要指标

Outcome:

DMFT

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

牙龈指数

指标类型:

主要指标

Outcome:

Gingival index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

菌斑指数

指标类型:

主要指标

Outcome:

Plaque index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

口腔相关生活治疗

指标类型:

主要指标

Outcome:

OHIP-14

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

头颈肿瘤生活治疗问卷

指标类型:

主要指标

Outcome:

FACT H&N

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

WHO口腔健康调查(成人)

指标类型:

主要指标

Outcome:

WHO oral health survey for adults

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

唾液

组织:

Sample Name:

saliva

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 23 years
最大 Max age 66 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2021.9, ResMan, http://www.medresman.org.cn.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2021.9, ResMan, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

2021.9, ResMan, http://www.medresman.org.cn.

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

2021.9, ResMan, http://www.medresman.org.cn.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-10-08 02:07:18